Ultragenyx Pharmaceutical, Inc. (RARE)
19.87
-0.55
(-2.69%)
USD |
NASDAQ |
Mar 20, 16:00
19.89
+0.02
(+0.10%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Research and Development Expense (Quarterly) : 194.22M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Corcept Therapeutics, Inc. | 64.86M |
| Johnson & Johnson | 4.268B |
| CorMedix, Inc. | 8.60M |
| BioMarin Pharmaceutical, Inc. | 192.41M |
| Insmed, Inc. | 254.91M |